Distinct compartmentalization of SP-A and SP-D in the vasculature and lungs of patients with idiopathic pulmonary fibrosis

BMC Pulmonary Medicine

Hiroki Takahashi¹  Yoshio Kuroki²  Atsushi Watanabe³  Kimiyuki Ikeda¹  Masanori Shiratori¹  Mitsuo Otsuka¹  Koji Kuronuma¹  Shigeru Ariki²  Hirofumi Chiba¹  Hirotaka Nishikiori¹ 

[1] Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, South-1 West-17, Chuo-ku, Sapporo 060-8556, Japan;Department of Biochemistry, Sapporo Medical University School of Medicine, Sapporo, Japan;Department of Thoracic Surgery, Sapporo Medical University School of Medicine, Sapporo, Japan

关键词: Compartmentalization;    Immunohistochemistry;    Hydrophilicity;    Biomarker;    Bronchoalveolar lavage;    Idiopathic pulmonary fibrosis;    SP-D;    SP-A;    Surfactant protein;   

Others  :  1090920
DOI  :  10.1186/1471-2466-14-196

 received in 2014-08-22, accepted in 2014-11-20,  发布年份 2014

【 摘 要 】

Background

Surfactant proteins SP-A and SP-D are useful biomarkers in diagnosis, monitoring, and prognosis of idiopathic pulmonary fibrosis (IPF). Despite their high structural homology, their serum concentrations often vary in IPF patients. This retrospective study aimed to investigate distinct compartmentalization of SP-A and SP-D in the vasculature and lungs by bronchoalveolar lavage fluid (BALF)/serum analysis, hydrophilicity and immunohistochemistry.

Methods

We included 36 IPF patients, 18 sarcoidosis (SAR) patients and 20 healthy subjects. Low-speed centrifugal supernatants of BALF (Sup-1) were obtained from each subject. Sera were also collected from each patient. Furthermore, we separated Sup-1 of IPF patients into hydrophilic supernatant (Sup-2) and hydrophobic precipitate (Ppt) by high-speed centrifugation. We measured SP-A and SP-D levels of each sample with the sandwich ELISA technique. We analyzed the change of the BALF/serum level ratios of the two proteins in IPF patients and their hydrophilicity in BALF. The distribution in the IPF lungs was also examined by immunohistochemical staining.

Results

In BALF, SP-A levels were comparable between the groups; however, SP-D levels were significantly lower in IPF patients than in others. Although IPF reduced the BALF/serum level ratios of the two proteins, the change in concentration of SP-D was more evident than SP-A. This suggests a higher disease impact for SP-D. Regarding hydrophilicity, although more than half of the SP-D remained in hydrophilic fractions (Sup-2), almost all of the SP-A sedimented in the Ppt with phospholipids. Hydrophilicity suggests that SP-D migrates into the blood more easily than SP-A in IPF lungs. Immunohistochemistry revealed that SP-A was confined to thick mucus-filling alveolar space, whereas SP-D was often intravascular. This data also suggests that SP-D easily leaks into the bloodstream, whereas SP-A remains bound to surfactant lipids in the alveolar space.

Conclusions

The current study investigated distinct compartmentalization of SP-A and SP-D in the vasculature and lungs. Our results suggest that serum levels of SP-D could reflect pathological changes of the IPF lungs more incisively than those of SP-A.

【 授权许可】

   
2014 Nishikiori et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Walker SR, Williams MC, Benson B: Immunocytochemical localization of the major surfactant apoprotein in type II cells, Clara cells and alveolar macrophages of rat lung. J Histochem Cytochem 1986, 34(9):1137-1148.
• [2]Voorhout WF, Veenendaal T, Kuroki Y, Ogasawara Y, van Golde LM, Geuze HJ: Immunocytochemical localization of surfactant protein (SP-D) in type II cells, Clara cells, and alveolar macrophages of rat lungs. J Histochem Cytochem 1992, 40(10):1589-1597.
• [3]Takahashi H, Sano H, Chiba H, Kuroki Y: Pulmonary surfactant proteins A and D: innate immune functions and biomarkers for lung diseases. Curr Pharm Des 2006, 12(5):589-598. Review
• [4]Ariki S, Nishitani C, Kuroki Y: Diverse functions of pulmonary collectins in host defense of the lung. J Biomed Biotechnol 2012, 2012:532071. Review
• [5]Takahashi H, Fujishima T, Koba H, Murakami S, Kurokawa K, Shibuya Y, Shiratori M, Kuroki Y, Abe S: Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent. Am J Respir Crit Care Med 2000, 162(3 Pt 1):1109-1114.
• [6]Greene KE, King TE Jr, Kuroki Y, Bucher-Bartelson B, Hunninghake GW, Newman LS, Nagae H, Mason RJ: Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis. Eur Respir J 2002, 19(3):439-446.
• [7]Persson A, Rust K, Chang D, Moxley M, Longmore W, Crouch E: CP4: a pneumocyte-derived collagenous surfactant-associated protein: evidence for heterogeneity of collagenous surfactant proteins. Biochemistry 1988, 27(23):8576-8584.
• [8]Persson A, Chang D, Rust K, Moxley M, Longmore W, Crouch E: Purification and biochemical characterization of CP4 (SP-D), a collagenous surfactant-associated protein. Biochemistry 1989, 28(15):6361-6367.
• [9]Kuroki Y, Akino T: Pulmonary Surfactant Protein A (SP-A) specifically binds dipalmitoylphosphatidylcholine. J Biol Chem 1991, 266(5):3068-3073.
• [10]Kuroki Y, Gasa S, Ogasawara Y, Makita A, Akino T: Binding of pulmonary surfactant protein A to galactosylceramide and asialo-GM2. Arch Biochem Biophys 1992, 299(2):261-267.
• [11]Ogasawara Y, Kuroki Y, Akino T: Pulmonary surfactant protein D specifically binds to phosphatidylinositol. J Biol Chem 1992, 267(29):21244-21249.
• [12]Kuroki Y, Gasa S, Ogasawara Y, Shiratori M, Makita A, Akino T: Binding specificity of lung surfactant protein SP-D for glucosylceramide. Biochem Biophys Res Commun 1992, 187(2):963-969.
• [13]Takahashi H, Shiratori M, Kanai A, Chiba H, Kuroki Y, Abe S: Monitoring markers of disease activity for interstitial lung diseases with serum surfactant proteins A and D. Respirology 2006, 11(Suppl):S51-S54.
• [14]Nathan SD, Shlobin OA, Weir N, Ahmad S, Kaldjob JM, Battle E, Sheridan MJ, du Bois RM: Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. Chest 2011, 140(1):221-229.
• [15]King TE Jr, Tooze JA, Schwarz MI, Brown KR, Cherniack RM: Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 2001, 164(7):1171-1181.
• [16]Mogulkoc N, Brutsche MH, Bishop PW, Greaves SM, Horrocks AW, Egan JJ, Greater Manchester Pulmonary Fibrosis Consortium: Pulmonary function in idiopathic pulmonary fibrosis and referral for lung transplantation. Am J Respir Crit Care Med 2001, 164(1):103-108.
• [17]Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK: Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003, 168(5):538-542.
• [18]Lama VN, Murray S, Mumford JA, Flaherty KR, Chang A, Toews GB, Peters-Golden M, Martinez FJ: Prognostic value of bronchiolitis obliterans syndrome stage 0-p in single-lung transplant recipients. Am J Respir Crit Care Med 2005, 172(3):379-383.
• [19]Kuroki Y, Tsutahara S, Shijubo N, Takahashi H, Shiratori M, Hattori A, Honda Y, Abe S, Akino T: Elevated levels of lung surfactant protein A in sera from patients with idiopathic pulmonary fibrosis and pulmonary alveolar proteinosis. Am Rev Respir Dis 1993, 147(3):723-729.
• [20]Yokoyama A, Kondo K, Nakajima M, Matsushima T, Takahashi T, Nishimura M, Bando M, Sugiyama Y, Totani Y, Ishizaki T, Ichiyasu H, Suga M, Hamada H, Kohno N: Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. Respirology 2006, 11(2):164-168.
• [21]Song JW, Do KH, Jang SJ, Colby TV, Han S, Kim DS: Blood biomarkers MMP-7 and SP-A: predictors of outcome in idiopathic pulmonary fibrosis. Chest 2013, 143(5):1422-1429.
• [22]Prasse A, Probst C, Bargagli E, Zissel G, Toews GB, Flaherty KR, Olschewski M, Rottoli P, Müller-Quernheim J: Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009, 179(8):717-723.
• [23]Morimoto T, Azuma A, Abe S, Usuki J, Kudoh S, Sugisaki K, Oritsu M, Nukiwa T: Epidemiology of sarcoidosis in Japan. Eur Respir J 2008, 31(2):372-379.
• [24]Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager H Jr, Bresnitz EA, DePalo L, Hunninghake G, Iannuzzi MC, Johns CJ, McLennan G, Moller DR, Newman LS, Rabin DL, Rose C, Rybicki B, Weinberger SE, Terrin ML, Knatterud GL, Cherniak R, Case Control Etiologic Study of Sarcoidosis (ACCESS) research group: Case Control Etiologic Study of Sarcoidosis (ACCESS) research group: clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001, 164(10 Pt 1):1885-1889.
• [25]Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, et al.: An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011, 183(6):788-824.
• [26]Honda Y, Takahashi H, Kuroki Y, Akino T, Abe S: Decreased contents of surfactant proteins A and D in BAL fluids of healthy smokers. Chest 1996, 109(4):1006-1009.
• [27]Shimizu H, Hosoda K, Mizumoto M, Kuroki Y, Sato H, Kataoka K, Hagisawa M, Fujimoto S, Akino T: Improved immunoassay for the determination of surfactant protein A (SP-A) in human amniotic fluid. Tohoku J Exp Med 1989, 157(3):269-278.
• [28]Bligh EG, Dyer WJ: A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959, 37(8):911-917.
• [29]Bartlett GR: Phosphorus assay in column chromatography. J Biol Chem 1959, 234(3):466-468.
• [30]Schlingemann RO, Rietveld FJR, de Waal RMW, Bradley NJ, Skene AI, Davies AJ, Greaves MF, Denekamp J, Ruiter DJ: Leukocyte antigen CD34 is expressed by a subset of cultured endothelial cells and on endothelial abluminal microprocesses in the tumor stroma. Lab Invest 1990, 62(6):690-696.
• [31]Kahn HJ, Marks A: A new monoclonal antibody, D2-40, for detection of lymphatic invasion in primary tumors. Lab Invest 2002, 82(9):1255-1257.
• [32]Honda Y, Kuroki Y, Matsuura E, Nagae H, Takahashi H, Akino T, Abe S: Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids. Am J Respir Crit Care Med 1995, 152(6 Pt 1):1860-1866.
• [33]McCormack FX, King TE Jr, Voelker DR, Robinson PC, Mason RJ: Idiopathic pulmonary fibrosis: abnormalities in the bronchoalveolar lavage content of surfactant protein A. Am Rev Respir Dis 1991, 144(1):160-166.
• [34]Günther A, Schmidt R, Nix F, Yabut-Perez M, Guth C, Rosseau S, Siebert C, Grimminger F, Morr H, Velcovsky HG, Seeger W: Surfactant abnormalities in idiopathic pulmonary fibrosis, hypersensitivity pneumonitis and sarcoidosis. Eur Respir J 1999, 14(3):565-573.
• [35]American Thoracic Society: Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000, 161(2 Pt):646-664.
• [36]Mogulkoc N, Brutsche MH, Bishop PW, Murby B, Greaves MS, Horrocks AW, Wilson M, McCullough C, Prescott M, Egan JJ, Greater Manchester Pulmonary Fibrosis Consortium: Pulmonary (99 m)Tc-DTPA aerosol clearance and survival in usual interstitial pneumonia (UIP). Thorax 2001, 56(12):916-923.
• [37]Burkhardt A: Alveolitis and collapse in the pathogenesis of pulmonary fibrosis. Am Rev Respir Dis 1989, 140(2):513-524. Review
• [38]Rinderknecht J, Shapiro L, Krauthammer M, Taplin G, Wasserman K, Uszler JM, Effros RM: Accelerated clearance of small solutes from the lungs in interstitial lung disease. Am Rev Respir Dis 1980, 121(1):105-117.
• [39]Kuroki Y, Shiratori M, Ogasawara Y, Tsuzuki A, Akino T: Characterization of pulmonary surfactant protain D:its copurification with lipids. Biochim Biophys Acta 1991, 1086(2):185-190.
• [40]Fina L, Molgaad HV, Robertson D, Bradley NJ, Monaghan P, Delia D, Sutherland DR, Baker MA, Greaves MF: Expression of the CD34 gene in vascular endothelial cells. Blood 1990, 75(12):2417-2426.
• [41]Ebina M, Shimizukawa M, Shibata N, Kimura Y, Suzuki T, Endo M, Sasano H, Kondo T, Nukiwa T: Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2004, 169(11):1203-1208.
• [42]Hisata S, Kimura Y, Shibata N, Ono S, Kobayashi T, Chiba S, Ohta H, Nukiwa T, Ebina M: A normal range of KL-6/MUC1 independent of elevated SP-D indicates a better prognosis in the patients with honeycombing on high-resolution computed tomography. Pulm Med. 2011, 2011:806014.
• [43]Meyer KC, Raghu G, Baughman RP, Brown KK, Costabel U, du Bois RM, Drent M, Haslam PL, Kim DS, Nagai S, Rottoli P, Saltini C, Selman M, Strange C, Wood B, American Thoracic Society Committee on BAL in Interstitial Lung Disease: An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med 2012, 185(9):1004-1014.